Invention Grant
- Patent Title: Therapy targeting cathepsin S
- Patent Title (中): 针对组织蛋白酶S的治疗
-
Application No.: US12296704Application Date: 2007-04-10
-
Publication No.: US09321838B2Publication Date: 2016-04-26
- Inventor: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
- Applicant: Shane Olwill , Christopher Scott , Julie Gormley , Jaquin Thomas , Roberta Burden , Darragh McMeel , James Johnston
- Applicant Address: GB
- Assignee: Fusion Antibodies Limited
- Current Assignee: Fusion Antibodies Limited
- Current Assignee Address: GB
- Agency: DLA Piper LLP (US)
- Priority: GB0607158.3 20060410; GB0620255.0 20061012
- International Application: PCT/GB2007/001312 WO 20070410
- International Announcement: WO2007/128987 WO 20071115
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; A61K31/00 ; A61K39/395 ; C07K16/40 ; G01N33/574 ; A61K39/00
Abstract:
The invention relates to a method of inhibiting chemotherapy induced upregulation of Cathepsin S on the surface of tumor cells, the method comprising the administration of a Cathepsin S inhibitor to said cells. Also provided is a therapy comprising an anti Cathepsin S antibody, in particular an anti-Cathepsin S antibody which does not inhibit the proteolytic effect of Cathepsin S but nevertheless inhibits angiogenesis and a combination treatment comprising a Cathepsin S inhibitor and a therapeutic agent.
Public/Granted literature
- US20090269360A1 THERAPY Public/Granted day:2009-10-29
Information query
